NVO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead the Novo Nordisk Class Action Lawsuit

Lawsuit Overview - The class action lawsuit against Novo Nordisk A/S alleges violations of the Securities Exchange Act of 1934 during the Class Period from November 2, 2022, to December 19, 2024 [1] - Investors who purchased or acquired Novo Nordisk securities during this period have until March 25, 2025, to seek appointment as lead plaintiff [1] Allegations Against Novo Nordisk - Defendants allegedly made false and/or misleading statements regarding the projected success of Novo Nordisk's phase 3 CagriSema study on obesity (REDEFINE-1) [3] - The company's claims of achieving at least 25% weight loss in the REDEFINE-1 study were allegedly unrealistic [3] - The use of a "flexible protocol" in the study limited its ability to provide accurate weight loss data, suggesting issues with dosage tolerability or patient selection [3] Impact on Novo Nordisk Stock - On December 20, 2024, Novo Nordisk disclosed headline results from the REDEFINE-1 trial, revealing that only 57.3% of patients treated with CagriSema were on the highest dose after 68 weeks [4] - Following this news, the price of Novo Nordisk stock fell nearly 18% [4] Lead Plaintiff Process - Any investor who purchased or acquired Novo Nordisk securities during the Class Period can seek appointment as lead plaintiff [5] - The lead plaintiff acts on behalf of all class members and can select a law firm to litigate the case [5] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in securities-related class action cases over the last four years [6] - The firm has 200 lawyers in 10 offices and has secured the largest securities class action recovery in history ($7.2 billion in In re Enron Corp. Sec. Litig.) [6]